The DICER1 antibody is a crucial tool for studying the DICER1 protein, a ribonuclease III enzyme encoded by the *DICER1* gene. This protein plays a pivotal role in processing precursor microRNAs (miRNAs) into mature miRNAs, which regulate gene expression by targeting mRNA for degradation or translational repression. Germline or somatic mutations in *DICER1* are linked to a hereditary cancer predisposition syndrome (DICER1 syndrome), associated with pleuropulmonary blastoma, ovarian Sertoli-Leydig cell tumors, thyroid malignancies, and other rare neoplasms. The DICER1 antibody enables detection and localization of the protein in tissues or cells, aiding in research on its expression patterns, functional roles, and dysregulation in disease. In diagnostics, it is employed in immunohistochemistry (IHC) or Western blotting to assess DICER1 loss or abnormal expression, which may correlate with tumorigenesis or guide genetic testing for germline mutations. Commercially available monoclonal or polyclonal antibodies target specific epitopes, though validation for specificity and sensitivity is critical due to potential cross-reactivity. Studies using DICER1 antibodies have enhanced understanding of its dual role as a tumor suppressor (via miRNA maturation) and context-dependent oncogene (through altered miRNA profiles). Its clinical utility extends to stratifying patient prognosis and monitoring therapeutic responses in DICER1-related disorders.